NCT05455619View on ClinicalTrials.gov

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 26, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions
HR+/HER2-negative Breast CancerMetastatic Breast Cancer
Interventions
DRUG

Evexomostat

Evexomostat (SDX-7320) is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.

Trial Locations (10)

17033

RECRUITING

Penn State Milton S Hershey Medical Center, Hershey

33176

RECRUITING

Miami Cancer Institute at Baptist Health, Miami

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

44195

RECRUITING

Cleveland Clinic, Cleveland

48197

RECRUITING

Trinity Health, Ypsilanti

60521

RECRUITING

Hope and Healing Cancer Services, Hinsdale

78045

RECRUITING

Doctors Hospital of Laredo, Laredo

92123

RECRUITING

SHARP Healthcare, San Diego

92354

RECRUITING

Loma Linda University Cancer Center, Loma Linda

92663

RECRUITING

Hoag Memorial Hospital Presbyterian, Newport

All Listed Sponsors
lead

SynDevRx, Inc.

INDUSTRY